Cystic Fibrosis-related Diabetes Onset Can Be Predicted Using Biomarkers Measured at Birth

Purpose: Cystic fibrosis (CF), caused by pathogenic variants in the CF transmembrane conductance regulator (CFTR), affects multiple organs including the exocrine pancreas, which is a causal contributor to cystic fibrosis-related diabetes (CFRD). Untreated CFRD causes increased CF-related mortality whereas early detection can improve outcomes.

Methods: Using genetic and easily accessible clinical measures available at birth, we constructed a CFRD prediction model using the Canadian CF Gene Modifier Study (CGS; n = 1,958) and validated it in the French CF Gene Modifier Study (FGMS; n = 1,003). We investigated genetic variants shown to associate with CF disease severity across multiple organs in genome-wide association studies.

Results: The strongest predictors included sex, CFTR severity score, and several genetic variants including one annotated to PRSS1, which encodes cationic trypsinogen. The final model defined in the CGS shows excellent agreement when validated on the FGMS, and the risk classifier shows slightly better performance at predicting CFRD risk later in life in both studies.

Conclusion: We demonstrated clinical utility by comparing CFRD prevalence rates between the top 10% of individuals with the highest risk and the bottom 10% with the lowest risk. A web-based application was developed to provide practitioners with patient-specific CFRD risk to guide CFRD monitoring and treatment.

Citing Articles

: New Potential Candidate Gene for Periventricular White Matter Abnormalities.

Cali F, Vinci M, Treccarichi S, Papa C, Gloria A, Musumeci A Genes (Basel). 2024; 15(8).

PMID: 39202455 PMC: 11353482. DOI: 10.3390/genes15081096.

Metabolomics Panel Associated with Cystic Fibrosis-Related Diabetes toward Biomarker Discovery.

Mujammami M, Nimer R, Al Mogren M, AlMalki R, Alabdaljabar M, Benabdelkamel H ACS Omega. 2024; 9(30):32873-32880.

PMID: 39100315 PMC: 11292812. DOI: 10.1021/acsomega.4c03626.

Precision medicine via the integration of phenotype-genotype information in neonatal genome project.

Dong X, Xiao T, Chen B, Lu Y, Zhou W Fundam Res. 2024; 2(6):873-884.

PMID: 38933389 PMC: 11197532. DOI: 10.1016/j.fmre.2022.07.003.

A provider survey of cystic fibrosis related diabetes screening and management practices at North American CF centers.

Hicks R, Ode K, Vigers T, Chan C Front Endocrinol (Lausanne). 2023; 14:1183288.

PMID: 37274323 PMC: 10232971. DOI: 10.3389/fendo.2023.1183288.

Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes.

Putman M, Norris A, Hull R, Rickels M, Sussel L, Blackman S Diabetes Care. 2023; 46(6):1112-1123.

PMID: 37125948 PMC: 10234745. DOI: 10.2337/dc23-0380.

References

Aksit M, Pace R, Vecchio-Pagan B, Ling H, Rommens J, Boelle P . Genetic Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes and Related Traits. J Clin Endocrinol Metab. 2019; 105(5). PMC: 7236628. DOI: 10.1210/clinem/dgz102. View

Peng S, Zhu Y, Lu B, Xu F, Li X, Lai M . TCF7L2 gene polymorphisms and type 2 diabetes risk: a comprehensive and updated meta-analysis involving 121,174 subjects. Mutagenesis. 2012; 28(1):25-37. DOI: 10.1093/mutage/ges048. View

Soave D, Corvol H, Panjwani N, Gong J, Li W, Boelle P . A Joint Location-Scale Test Improves Power to Detect Associated SNPs, Gene Sets, and Pathways. Am J Hum Genet. 2015; 97(1):125-38. PMC: 4572492. DOI: 10.1016/j.ajhg.2015.05.015. View

Moran A, Brunzell C, Cohen R, Katz M, Marshall B, Onady G . Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010; 33(12):2697-708. PMC: 2992215. DOI: 10.2337/dc10-1768. View

Adler A, Shine B, Chamnan P, Haworth C, Bilton D . Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults. Diabetes Care. 2008; 31(9):1789-94. PMC: 2518346. DOI: 10.2337/dc08-0466. View

Dudbridge F . Power and predictive accuracy of polygenic risk scores. PLoS Genet. 2013; 9(3):e1003348. PMC: 3605113. DOI: 10.1371/journal.pgen.1003348. View

Thompson E, Watson D, Benoit C, Landvik S, McNamara J . The association of pediatric cystic fibrosis-related diabetes screening on clinical outcomes by center: A CF patient registry study. J Cyst Fibros. 2019; 19(2):316-320. DOI: 10.1016/j.jcf.2019.07.010. View

Moran A, Hardin D, Rodman D, ALLEN H, Beall R, Borowitz D . Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract. 1999; 45(1):61-73. DOI: 10.1016/s0168-8227(99)00058-3. View

Blackman S, Commander C, Watson C, Arcara K, Strug L, Stonebraker J . Genetic modifiers of cystic fibrosis-related diabetes. Diabetes. 2013; 62(10):3627-35. PMC: 3781476. DOI: 10.2337/db13-0510. View

10.

Soave D, Miller M, Keenan K, Li W, Gong J, Ip W . Evidence for a causal relationship between early exocrine pancreatic disease and cystic fibrosis-related diabetes: a Mendelian randomization study. Diabetes. 2014; 63(6):2114-9. PMC: 4030111. DOI: 10.2337/db13-1464. View

11.

Thomassen J, Mueller M, Alejandre Alcazar M, Rietschel E, van Koningsbruggen-Rietschel S . Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients. J Cyst Fibros. 2017; 17(2):271-275. DOI: 10.1016/j.jcf.2017.11.016. View

12.

Ooi C, Dorfman R, Cipolli M, Gonska T, Castellani C, Keenan K . Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology. 2010; 140(1):153-61. DOI: 10.1053/j.gastro.2010.09.046. View

13.

Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C . Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros. 2019; 19(1):68-79. DOI: 10.1016/j.jcf.2019.05.015. View

14.

Gibson-Corley K, Meyerholz D, Engelhardt J . Pancreatic pathophysiology in cystic fibrosis. J Pathol. 2015; 238(2):311-20. PMC: 4699289. DOI: 10.1002/path.4634. View

15.

Sarles J, Giorgi R, Berthezene P, Munck A, Cheillan D, Dagorn J . Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP. J Cyst Fibros. 2014; 13(4):384-90. DOI: 10.1016/j.jcf.2014.01.004. View

16.

Boudreau V, Coriati A, Hammana I, Ziai S, Desjardins K, Berthiaume Y . Variation of glucose tolerance in adult patients with cystic fibrosis: What is the potential contribution of insulin sensitivity?. J Cyst Fibros. 2016; 15(6):839-845. DOI: 10.1016/j.jcf.2016.04.004. View

17.

Sun L, Dimitromanolakis A, Faye L, Paterson A, Waggott D, Bull S . BR-squared: a practical solution to the winner's curse in genome-wide scans. Hum Genet. 2011; 129(5):545-52. PMC: 3074069. DOI: 10.1007/s00439-011-0948-2. View

18.

Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W . Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009; 32(9):1626-31. PMC: 2732133. DOI: 10.2337/dc09-0586. View

19.

Xiao R, Boehnke M . Quantifying and correcting for the winner's curse in genetic association studies. Genet Epidemiol. 2009; 33(5):453-62. PMC: 2706290. DOI: 10.1002/gepi.20398. View

20.

Lewis C, Blackman S, Nelson A, Oberdorfer E, Wells D, Dunitz J . Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med. 2014; 191(2):194-200. PMC: 4347432. DOI: 10.1164/rccm.201403-0576OC. View